<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614052</url>
  </required_header>
  <id_info>
    <org_study_id>171229002</org_study_id>
    <nct_id>NCT03614052</nct_id>
  </id_info>
  <brief_title>Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy</brief_title>
  <official_title>Efectividad de la Tamsulosina Como Tratamiento Adyuvante Previo a Ureterolitotomia Endoscopica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a study aiming to compare treatment with tamsulosin versus placebo in patients
      undergoing endoscopic treatment for urolithiasis. The main outcome is the rate of stone free
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic treatment of urolithiasis has increased during the last several years. Adrenergic
      receptors have been described mainly in the distal ureter. Blockage of adrenergic receptors
      has been associated to a decrease in ureteral resistance. In this study the investigators
      hypothesized that alpha blockers are associated to a decrease in ureteral resistance with an
      increase in successful endoscopic management of urolithiasis.

      Only patients with urolithiasis undergoing to endoscopic treatment are offered to
      participate. Patients are randomized between placebo arm or tamsulosin 0.4 mg/day.
      Demographic characteristics, stones characteristics and information related to surgery are
      recorded. Main study outcome is stone free rate and successful insertion of semirigid
      ureteroscope 8,0 - 9,8 Fr. All patients are follow-up for 30 days after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Problems with the number of participants
  </why_stopped>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">January 26, 2020</completion_date>
  <primary_completion_date type="Actual">January 26, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stone free rate</measure>
    <time_frame>30 days</time_frame>
    <description>stone free rate after ureteroscopic management of urolithiasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>failed ureteroscopy rate</measure>
    <time_frame>05 days</time_frame>
    <description>failed ureteroscopy insertion in patient with urolithiasis secondary to a non accommodating ureter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Ureterolithiasis</condition>
  <condition>Ureteral Calculi</condition>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>tamsulosin hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablets by mouth per day for 5 days before ureteroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin Hydrochloride 0.4 milligrams</intervention_name>
    <description>Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis</description>
    <arm_group_label>tamsulosin hydrochloride</arm_group_label>
    <other_name>tamsulosin0,4mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis</description>
    <arm_group_label>Placebo oral tablet</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with urolithiasis undergoing to endoscopic ureterolithotomy

        Exclusion Criteria:

          -  Patients with previous ureteral catheter

               -  Patients with allergy to tamsulosin

               -  Patients currently in treatment with tamsulosin for other disease different than
                  ureterolithiasis

               -  Multiple ureterolithiasis

               -  Patients with impairment of their mental status

                    -  Patients with open surgeries in the affected ureter or urinary diversion

                    -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaston Astroza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico Pontificia Universidad cat√≥lica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

